Transfer factor in the treatment of chronic mucocutaneous candidiasis: a controlled study.

Abstract

A controlled cross-over study with transfer factor was carried out on 7 patients suffering from chronic mucocutaneous candidiasis. Only one patient showed clinical improvement, which started during a period of pretreatment with 5-fluorocytosine given orally 14 days before the patient entered this trial. No conversion to a positive skin test with Candida antigen or PPD was demonstrated following TF in the 6 patients who were anergic to either of these antigens. Variations in the cell-mediated immune response as revealed by lymphocyte transformation were observed in most patients, especially when studied over a long period of time. However, no pronounced efficacy of TF vis-à-vis placebo in normalizing the cell-mediated immune response could be demonstrated in the 5 patients who completed the clinical trial. Systemic side effects were not observed.

• Authors: H Mobacken, L A Hanson, L Lindholm, C Ljunggren
• Journal: Acta dermato-venereologica (Acta Derm Venereol) Vol. 60 Issue 1 Pg. 51-5 ( 1980) ISSN: 0001-5555 [Print] Sweden
• PMID: 6153834 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Placebos
• Transfer Factor
• Flucytosine

Topics

• Adolescent
• Adult
• Candidiasis, Cutaneous (drug therapy, immunology, therapy)
• Child
• Child, Preschool
• Chronic Disease
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Flucytosine (therapeutic use)
• Humans
• Male
• Mucous Membrane (pathology)
• Placebos
• Skin Tests
• Transfer Factor (therapeutic use)